A Japanese research team is currently working on a groundbreaking medication that shows promise in enabling people to grow new teeth. Clinical trials for this tooth regrowth medicine are scheduled to begin in July 2024, with the aim of making it available for general use by 2030. The medication is primarily intended for individuals who have congenital factors resulting in an incomplete set of adult teeth. Anodontia, a condition where fewer than a full set of teeth develop, affects approximately 1% of the population. Among those with anodontia, about one-tenth have oligodontia, which means they are missing six or more teeth. These conditions, also known as tooth agenesis, are primarily caused by genetic factors. People with tooth agenesis face challenges in basic functions like chewing, swallowing, and speaking from a young age, which can negatively impact their overall development.   The lead researcher of this project is Katsu Takahashi, who heads the dentistry and oral surg...